García-León FE, López-Benítez SV, Pablos VG, Medina-Ramos G, Ramírez-Diarte EA, Uriarte-Ontiveros S

Language: Spanish
References: 14
Page: 21-24
PDF size: 124.40 Kb.

ABSTRACT

Introduction: it implants subskin is a method of prolonged liberation of only progestinas, through the wall of capsules placed underneath the skin. The concept of contraceptive by means of implants of prolonged liberation was proposed in 1967 by the Population Council. In Mexico, Implanon is available from the 2001 in the basic picture of the IMSS, ISSSTE and SSA.
Objective: to determine the frequency of adverse effects in the users with implants subskin.
Methodology: study was realized descriptive survey, to 162 users of the Familiar Medicine Unit 46. A valuation instrument was elaborated on the frequency of adverse effects of implants subskin, which validated by two rounds of experts and one pilot test.
Results: the average of age of the users was of 25.2 years, with a standard deviation ± 4.5. 28.3% of the users with implant subskin presented/displayed adverse effects, emphasizing the following: 36% alterations in the menstrual cycle, headache 28%, increase of weight 12%, mareos 12% and changes in the mood 12%.
Conclusions: the frequency of adverse effects in users with implants subskin is significant and agrees with other realized investigations.

REFERENCES

1. Otero Flores Braulio. 2007. Manual de actualización en metodología anticonceptiva. México: Laboratorios Organon. pp. 39-47.2

2. Organon Mexicana. Guía didáctica del implante subdérmico con Etonogestrel. México: Laboratorios Shering-Plough. pp. 1-5.

3. Baird DT, Glasier AF. Science, medicine, and the future. Contraception. BMJ. 1999; 319(7215):969-72.

4. Vasconcelos AM, Unda UM. Implantes anticonceptivos de levonorgestrel. Realidades y controversias de un método anticonceptivo actual. Ginecol Obstet Mex. 1996;64(11):498-502.

5. Montenegro-Pereira E, Lara-Ricalde R, Velásquez- Ramírez N. Implantes anticonceptivos. Perinatol Reprod Hum. 2005;19(1): 31-43. [En línea] http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S018753372005000100005&lng=es. [Consultado 27/04/2011].

6. Secretaría de Salud (México). Norma Oficial Mexicana NOM-005-SSA2-1993 de los servicios de planificación familiar (modificada). México: Secretaría de Salud, 2004. pp. 58.

7. Mascarenhas L. Insertion and removal of Implanon. Contraception. 1998;58(6 Suppl): 79S-83S.

8. Patiño VA, Ruelas CMR, Villarreal R, Martínez GL, Galicia RL, Vargas DER. Evolución a un año de los efectos adversos, en una cohorte de pacientes con implante subdérmico de desogestrel. Rev Chil Obstet Ginecol. 2006;71(3):170-173. [En línea] Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-75262006000300005&lng=es. [Consultado 27/04/2011].

9. Carbajal-Ugarte JA, Cárdenas-Blanco A, Pastrana-Huanaco E, López-Berrios D. Eficacia y efectos adversos de anticonceptivos hormonales. Estudio comparativo Rev Med Inst Mex Seguro Soc. 2008;46(1):83-87.

10. Lugones Botell M, Quintana Riverón TY, Cruz Oviedo Y. Anticoncepción hormonal. Rev Cubana Med Gen Integr. 1997;13(1): 49-58. [En línea] http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21251997000100009&lng=es. [Consultado 27/04/2011].

11. Bitzer J, Tschudin S, Alder J, Swiss Implanon Study Group. Acceptability and sideeffects of Implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care. 2004;9(4):278-84.

12. Booranabunyat S, Taneepanichskul S. Implanon use in Thai women above the age of 35 years. Contraception. 2004;69(6): 489-91.

13. Cardona Pérez Jorge. 2006. Guía didáctica del implante subdérmico con etonogestrel. Ediciones del Instituto Mexicano del Seguro Social. DF, México. Pág.:11-35.

14. Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanon. Contraception. 1998;58(6 Suppl):109S-115S.